Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain

J. M. Minke, L. Siger, L. Cupillard, B. Powers, T. Bakonyi, S. Boyum, N. Nowotny, R. Bowen

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines, all based on lineage 1 strains, protect against circulating lineage 2 strains of WNV. In the present paper we have determined the level of cross protection provided by the recombinant ALVAC®-WNV vaccine in a severe challenge model that produces clinical signs of WNV type 2 disease. Ten horses were vaccinated twice at 4 weeks interval with one dose of the ALVAC-WNV vaccine formulated at the minimum protective dose. A further 10 horses served as controls. Two weeks after the second vaccination, all horses were challenged intrathecally with a recent neurovirulent lineage 2 strain of WNV. The challenge produced viraemia in 10 out of 10 and encephalitis in 9 out of 10 control horses. Three horses had to be euthanized for humane reasons. In contrast, none of the vaccinated horses developed WNV disease and only 1 vaccinated horse became viraemic at a single time point at low titre. The prevalence of WNV disease and viraemia were significantly lower in the vaccinated horses than in the control horses (P

Original languageEnglish
Pages (from-to)4608-4612
Number of pages5
JournalVaccine
Volume29
Issue number28
DOIs
Publication statusPublished - Jun 20 2011

Fingerprint

Horses
vaccines
horses
Genes
genes
Viremia
viremia
ALVAC vaccine
Cross Protection
disease prevalence
Encephalitis
encephalitis
dosage
Vaccination
Vaccines
vaccination
Mortality

Keywords

  • Cross protection
  • Horse
  • Intrathecal challenge
  • Recombinant ALVAC®-WNV vaccine
  • WNV lineage 1 and 2

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain. / Minke, J. M.; Siger, L.; Cupillard, L.; Powers, B.; Bakonyi, T.; Boyum, S.; Nowotny, N.; Bowen, R.

In: Vaccine, Vol. 29, No. 28, 20.06.2011, p. 4608-4612.

Research output: Contribution to journalArticle

Minke, J. M. ; Siger, L. ; Cupillard, L. ; Powers, B. ; Bakonyi, T. ; Boyum, S. ; Nowotny, N. ; Bowen, R. / Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain. In: Vaccine. 2011 ; Vol. 29, No. 28. pp. 4608-4612.
@article{97ed771be85a419e9820c2598e9e777a,
title = "Protection provided by a recombinant ALVAC{\circledR}-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain",
abstract = "The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines, all based on lineage 1 strains, protect against circulating lineage 2 strains of WNV. In the present paper we have determined the level of cross protection provided by the recombinant ALVAC{\circledR}-WNV vaccine in a severe challenge model that produces clinical signs of WNV type 2 disease. Ten horses were vaccinated twice at 4 weeks interval with one dose of the ALVAC-WNV vaccine formulated at the minimum protective dose. A further 10 horses served as controls. Two weeks after the second vaccination, all horses were challenged intrathecally with a recent neurovirulent lineage 2 strain of WNV. The challenge produced viraemia in 10 out of 10 and encephalitis in 9 out of 10 control horses. Three horses had to be euthanized for humane reasons. In contrast, none of the vaccinated horses developed WNV disease and only 1 vaccinated horse became viraemic at a single time point at low titre. The prevalence of WNV disease and viraemia were significantly lower in the vaccinated horses than in the control horses (P",
keywords = "Cross protection, Horse, Intrathecal challenge, Recombinant ALVAC{\circledR}-WNV vaccine, WNV lineage 1 and 2",
author = "Minke, {J. M.} and L. Siger and L. Cupillard and B. Powers and T. Bakonyi and S. Boyum and N. Nowotny and R. Bowen",
year = "2011",
month = "6",
day = "20",
doi = "10.1016/j.vaccine.2011.04.058",
language = "English",
volume = "29",
pages = "4608--4612",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "28",

}

TY - JOUR

T1 - Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain

AU - Minke, J. M.

AU - Siger, L.

AU - Cupillard, L.

AU - Powers, B.

AU - Bakonyi, T.

AU - Boyum, S.

AU - Nowotny, N.

AU - Bowen, R.

PY - 2011/6/20

Y1 - 2011/6/20

N2 - The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines, all based on lineage 1 strains, protect against circulating lineage 2 strains of WNV. In the present paper we have determined the level of cross protection provided by the recombinant ALVAC®-WNV vaccine in a severe challenge model that produces clinical signs of WNV type 2 disease. Ten horses were vaccinated twice at 4 weeks interval with one dose of the ALVAC-WNV vaccine formulated at the minimum protective dose. A further 10 horses served as controls. Two weeks after the second vaccination, all horses were challenged intrathecally with a recent neurovirulent lineage 2 strain of WNV. The challenge produced viraemia in 10 out of 10 and encephalitis in 9 out of 10 control horses. Three horses had to be euthanized for humane reasons. In contrast, none of the vaccinated horses developed WNV disease and only 1 vaccinated horse became viraemic at a single time point at low titre. The prevalence of WNV disease and viraemia were significantly lower in the vaccinated horses than in the control horses (P

AB - The emergence of lineage 2 strains of WNV in Europe as a cause of clinical disease and mortality in horses raised the question whether the existing WNV vaccines, all based on lineage 1 strains, protect against circulating lineage 2 strains of WNV. In the present paper we have determined the level of cross protection provided by the recombinant ALVAC®-WNV vaccine in a severe challenge model that produces clinical signs of WNV type 2 disease. Ten horses were vaccinated twice at 4 weeks interval with one dose of the ALVAC-WNV vaccine formulated at the minimum protective dose. A further 10 horses served as controls. Two weeks after the second vaccination, all horses were challenged intrathecally with a recent neurovirulent lineage 2 strain of WNV. The challenge produced viraemia in 10 out of 10 and encephalitis in 9 out of 10 control horses. Three horses had to be euthanized for humane reasons. In contrast, none of the vaccinated horses developed WNV disease and only 1 vaccinated horse became viraemic at a single time point at low titre. The prevalence of WNV disease and viraemia were significantly lower in the vaccinated horses than in the control horses (P

KW - Cross protection

KW - Horse

KW - Intrathecal challenge

KW - Recombinant ALVAC®-WNV vaccine

KW - WNV lineage 1 and 2

UR - http://www.scopus.com/inward/record.url?scp=79958105030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958105030&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.04.058

DO - 10.1016/j.vaccine.2011.04.058

M3 - Article

C2 - 21549780

AN - SCOPUS:79958105030

VL - 29

SP - 4608

EP - 4612

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 28

ER -